← Human Trials & Peer-Reviewed Studies
Assessment of angiotensin II receptor blockade in humans using a standardized angiotensin II receptor-binding assay
Plain-language guide to PMID 10619583 (1999): double-blind randomized controlled trial study of Angiotensin II in 12 subjects.
Key Facts
- PMID
- 10619583
- Journal
- American journal of hypertension
- Year
- 1999
- Study type
- Randomized Controlled Trial
- Authors
- Maillard MP et al. (7 authors)
- DOI
- 10.1016/s0895-7061(99)00133-8
What This Study Did, in Plain Language
What Was Tested
The paper reports a study of Angiotensin II, published as a randomized controlled trial.
An in vitro angiotensin II (AngII) receptor-binding assay was developed to monitor the degree of receptor blockade in standardized conditions.
This in vitro method was validated by comparing its results with those obtained in vivo with the injection of exogenous AngII and the measurement of the AngII-induced changes in systolic blood pressure.
Who Took Part
The study group was 12 subjects.
How the Study Was Run
The researchers set it up as a randomized, double-blind, placebo-controlled and crossover study.
Random assignment meant chance, not the researchers, decided who got Angiotensin II and who got the comparison, which limits bias.
Neither the subjects nor the staff measuring them knew who was on Angiotensin II, so expectations could not easily colour the readings.
Some subjects received a placebo instead of Angiotensin II, giving a reference point.
In the crossover set-up each of the subjects took both Angiotensin II and the comparison in turn, acting as their own control.
What Was Measured
This in vitro method was validated by comparing its results with those obtained in vivo with the injection of exogenous AngII and the measurement of the AngII-induced changes in systolic blood pressure.
Topics PubMed links to this paper include Angiotensin II, Angiotensin Receptor Antagonists, Antihypertensive Agents, Biomarkers, Biphenyl Compounds, Blood Pressure and Hypertension.
What This Means in Plain Language
The paper is a randomized, double-blind and placebo-controlled study of Angiotensin II in 12 subjects.
With fewer than 40 people, it is a small study, so it is better read as an early signal for further research than as a settled answer.
The publication is from 1999 (American journal of hypertension), a journal based in United States.
More context: the Angiotensin II compound page, all human trials.
Our Notes on the Compound
Angiotensin II: An 8-amino-acid hormone that narrows blood vessels; synthetic angiotensin II (Giapreza) is used for low blood pressure in shock.
Related Pages
Source: PubMed record. This explanation is written by PeptideWhiz from the public record. For research and education only. Not medical advice; no dosing information is given.